南開科技大學圖書館 |

回首頁

The Biotech Agethe business of biotech and how to profit from it /

紀錄類型:	書目-電子資源 : 單行本
正題名/作者:	The Biotech Age/ Richard W. Oliver.
其他題名:	the business of biotech and how to profit from it /
作者:	Oliver, Richard W.,
出版者:	New York :McGraw-Hill,c2003.
面頁冊數:	1 online resource (xviii, 253 p.) :ill.
附註:	Includes index.
標題:	Biotechnology industries. -
電子資源:	Click here for online access to this book (查閱全文) (EBSCO eBook)
ISBN:	0071425004 (electronic bk.)
ISBN:	9780071425001 (electronic bk.)
ISBN:	9780071414890 (pbk. : alk. paper)
ISBN:	0071414894 (pbk. : alk. paper)
ISBN:	1280229241
ISBN:	9781280229244

The Biotech Agethe business of biotech and how to profit from it /
Oliver, Richard W.,1946-

The Biotech Agethe business of biotech and how to profit from it /[electronic resource] :Richard W. Oliver. - New York :McGraw-Hill,c2003. - 1 online resource (xviii, 253 p.) :ill.

Includes index.

Introduction--the bioterials century -- The twenty first century -- Conquering matter -- Bioterials, the new economic engine -- The three laws of bio-economics -- New materials -- Designer genes -- Betting the "pharma" -- Betting the farm -- Financing the dream -- The war on genes -- The DNA divide.

Since The Coming BioTech Age was published in 1999, much has changed in this fast-moving, volatile industry. Furthermore, media attention on biotech, especially ethical and legislative issues, has increased several times over. Biotech companies are featured regularly in business publications and general interest magazines and newspapers are running stories on cloning and stem cell research on an almost daily basis. Major developments that have taken place since the book was published, The human genome was mapped by Celera Genomics in June, 2000, well ahead of schedule, just a few months after a rough draft was finished. Stem cell research has become front-page news, with debates in Congress, the White House, and the public forums being hotly contested. The politically powerful "Right to Life" camp has split down the middle on the issue. Funding and investment in biotech have increased at a rapid pace, with the tech meltdown having little effect on the biotech environment. Market capitalization increased from USD138 billion when the book was written to over USD330 billion in 2001, despite declines in the overall markets.; There are now more than 350 biotech drugs and vaccines in clinical trials, targeting more than 200 diseases. Total sales and revenues in at biotech companies both increased over 10 percent in the year following the book's publishing, despite the ongoing recession. Medical biotech companies have gained much more clout in negotiations with Big Pharma, especially after raising a record USD31 billion in 2000. In 2001, GM crops comprised 74 percent of all soybeans grown in the US, 71 percent of all cotton, and 32 percent of all corn. In 2000, the US Supreme Court upheld the rights of companies to patent hybrid and genetically modified plants. All of the above and more - including a new introduction and conclusion - will be covered in this completely revised and updated paperback edition.

ISBN: 0071425004 (electronic bk.)

OverDrive, Inc.http://www.overdrive.comSubjects--Topical Terms:

157522
Biotechnology industries.
Index Terms--Genre/Form:

172687
Electronic books.

LC Class. No.: HD9999.B442 / O438 2003eb

Dewey Class. No.: 338.4/76606

The Biotech Agethe business of biotech and how to profit from it /
LDR:04275nmm 2200421Ia 4500 001 1000049489
005 20140829032257.0
006 m o d
007 cr cnu---unuuu
008 031117s2003 nyua o 001 0 eng d
019 $a 53457845 $a 133161791 $a 276793845 $a 531098284 $a 560205804 $a 647636214 $a 722525366 $a 728040932 $a 793528416 $a 814286850
020 $a 0071425004 (electronic bk.)
020 $a 9780071425001 (electronic bk.)
020 $a 9780071414890 (pbk. : alk. paper)
020 $a 0071414894 (pbk. : alk. paper)
020 $a 1280229241
020 $a 9781280229244
035 $a (OCoLC)53448137 $z (OCoLC)53457845 $z (OCoLC)133161791 $z (OCoLC)276793845 $z (OCoLC)531098284 $z (OCoLC)560205804 $z (OCoLC)647636214 $z (OCoLC)722525366 $z (OCoLC)728040932 $z (OCoLC)793528416 $z (OCoLC)814286850
035 $a ocm53448137
037 $b OverDrive, Inc. $n http://www.overdrive.com
040 $a N$T $b eng $c N$T $d YDXCP $d OCLCG $d OCLCQ $d TUU $d OCLCQ $d TNF $d MERUC $d CCO $d E7B $d TEFOD $d IDEBK $d COCUF $d CAI $d QT5 $d FVL $d OCLCQ $d GRPVE $d OCLCO $d OCLCQ $d OCLCF
049 $a MAIN{me_controlnum}
050 4 $a HD9999.B442 $b O438 2003eb
072 7 $a BUS $x 070080 $2 bisacsh
072 7 $a KM $2 bicssc
082 0 4 $a 338.4/76606 $2 22
100 1 $a Oliver, Richard W., $d 1946- $3 153369
245 1 4 $a The Biotech Age $h [electronic resource] : $b the business of biotech and how to profit from it / $c Richard W. Oliver.
260 $a New York : $b McGraw-Hill, $c c2003.
300 $a 1 online resource (xviii, 253 p.) : $b ill.
500 $a Includes index.
505 0 $a Introduction--the bioterials century -- The twenty first century -- Conquering matter -- Bioterials, the new economic engine -- The three laws of bio-economics -- New materials -- Designer genes -- Betting the "pharma" -- Betting the farm -- Financing the dream -- The war on genes -- The DNA divide.
520 $a Since The Coming BioTech Age was published in 1999, much has changed in this fast-moving, volatile industry. Furthermore, media attention on biotech, especially ethical and legislative issues, has increased several times over. Biotech companies are featured regularly in business publications and general interest magazines and newspapers are running stories on cloning and stem cell research on an almost daily basis. Major developments that have taken place since the book was published, The human genome was mapped by Celera Genomics in June, 2000, well ahead of schedule, just a few months after a rough draft was finished. Stem cell research has become front-page news, with debates in Congress, the White House, and the public forums being hotly contested. The politically powerful "Right to Life" camp has split down the middle on the issue. Funding and investment in biotech have increased at a rapid pace, with the tech meltdown having little effect on the biotech environment. Market capitalization increased from USD138 billion when the book was written to over USD330 billion in 2001, despite declines in the overall markets.; There are now more than 350 biotech drugs and vaccines in clinical trials, targeting more than 200 diseases. Total sales and revenues in at biotech companies both increased over 10 percent in the year following the book's publishing, despite the ongoing recession. Medical biotech companies have gained much more clout in negotiations with Big Pharma, especially after raising a record USD31 billion in 2000. In 2001, GM crops comprised 74 percent of all soybeans grown in the US, 71 percent of all cotton, and 32 percent of all corn. In 2000, the US Supreme Court upheld the rights of companies to patent hybrid and genetically modified plants. All of the above and more - including a new introduction and conclusion - will be covered in this completely revised and updated paperback edition.
588 $a Description based on print version record.
650 0 $a Biotechnology industries. $3 157522
650 7 $a BUSINESS & ECONOMICS $x Industries $x Service. $2 bisacsh $3 1000062222
650 7 $a Electronic books. $3 170701
655 4 $a Electronic books. $2 local. $3 172687
776 0 8 $i Print version: $a Oliver, Richard W., 1946- $t Biotech Age. $d New York : McGraw-Hill, c2003 $z 0071414894 $w (DLC) 2003002228 $w (OCoLC)51607459
856 4 0 $3 EBSCOhost $u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=99797 $z Click here for online access to this book (查閱全文) (EBSCO eBook)
938 $a YBP Library Services $b YANK $n 2277682
938 $a ebrary $b EBRY $n ebr10152918
938 $a EBSCOhost $b EBSC $n 99797
938 $a Ingram Digital eBook Collection $b IDEB $n 22924